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The interplay of environmental and genetic factors in the devel-
opmental organization of the hippocampus has not been fully
elucidated. The neuropeptide corticotropin-releasing factor (CRF) is
released from hippocampal interneurons by environmental sig-
nals, including stress, to increase synaptic efficacy. In the early
postnatal hippocampus, we have previously characterized a tran-
sient population of CRF-expressing Cajal–Retzius-like cells. Here we
queried whether this stress-activated neuromodulator influences
connectivity in the developing hippocampal network. Using mice
deficient in the principal hippocampal CRF receptor [CRF1()]
and organotypic cultures grown in the presence of synthetic CRF,
or CRF receptor antagonists, we found robust effects of CRF on
dendritic differentiation in hippocampal neurons. In CRF1()
mice, the dendritic trees of hippocampal principal cells were
exuberant, an effect that was induced in normal hippocampi in
vitro by the presence of CRF1 antagonists. In both cases, total
dendritic length and dendritic branching were significantly in-
creased. In contrast, exogenous synthetic CRF blunted the dendritic
growth in hippocampal organotypic cultures. Taken together,
these findings suggest that endogenous CRF, if released exces-
sively by previous early postnatal stress, might influence neuronal
connectivity and thus function of the immature hippocampus.
corticotropin-releasing hormone  stress  corticotropin-releasing factor
receptor  neuropeptide  Cajal–Retzius cells
The developmental organization of the hippocampal networkis a complex process, requiring the interplay of genetic and
environmental factors. Establishment of basic hippocampal con-
nectivity is governed by genetically determined mechanisms,
including the coordinated activation of transcription factors
(1–3), and the expression of both local and more generally acting
guidance molecules (4–6). Once the basic elements are in place,
refinement of connectivity is achieved through environmental
stimuli that influence neuronal activity (7–9). Among the ele-
ments that contribute to developmental organization of the
hippocampus are the Cajal–Retzius (CR) cells (10, 11). CR cells,
found in hippocampal marginal zones, release reelin, an extra-
cellular matrix protein required for layer formation and posi-
tioning of cortical neurons (12, 13). Because lack of reelin causes
perturbation of cortical lamination (14), control of neuronal
positioning has been considered the major function of CR cells.
However, recent results suggest additional roles for CR cells that
are independent of reelin (15–18).
We have previously characterized a subset of CR cells that do
not express reelin but release the neuropeptide corticotropin-
releasing factor (CRF). CRF functions primarily as a regulator
of the neuroendocrine stress response (19, 20) but is also widely
expressed within the central nervous system, where it acts as a
neuromodulator (21–24). In mature hippocampus, although
CRF is exclusively expressed in GABAergic interneurons (18,
25, 26), its physiological actions are excitatory (21, 27), enhanc-
ing synaptic efficacy (28, 29). Thus, in mature hippocampus,
CRF activates and stabilizes synaptic transmission.
The role of CRF derived from CR cells and other CRF-
expressing neurons in immature hippocampus has remained
elusive (18). Here we investigated the function(s) of CRF in
developing hippocampus by using CRF receptor-deficient
[CRF1()] mice and in vitro hippocampal organotypic cul-
tures exposed to exogenous CRF or to specific CRF1 antagonist
NBI 30775 (30–32). Our results indicate that CRF influences
dendritic differentiation, an essential component of neuronal
communication. These findings suggest new roles for hippocam-
pal CRF and for CRF-expressing CR cells.
Materials and Methods
Animals. Sprague–Dawley rats [postnatal days (P) 0–7] and
CRF1() P6–P7 mice (C57 background) were used. Mice
were genotyped by PCR (33), and CRF1() mice were
compared to CRF1() littermates (WT). Animals were
maintained in uncrowded, National Institutes of Health-
approved facilities on a 12-h light cycle, with ad libitum access
to lab chow and water. Experiments were approved by University
of California and Federal Animal Care Committees.
Organotypic Slice Cultures and Manipulation of CRF Receptor Activa-
tion. Entorhinal cortex–hippocampal cultures (n  338) were
prepared from P0–P1 rat brains (34). Concentrations of CRF1
antagonist NBI 30775 {3-[6-(dimethylamino)-4-methyl-pyrid-3-
yl]-2,5-dimethyl-N,N-dipropyl-pyrazolo[2,3-a]pyrimidin-7-
amine, previously R121919} were 0.1 or 1 M (for Golgi studies;
n  60 per group) and 0.01, 0.1, or 10 M (for calbindin D-28K;
n  6–10); those of CRF (n  56; Bachem) were 1 M.
Tissue Processing and Immunocytochemistry. Animals were anes-
thetized and then perfused with a formaldehyde solution made
from 4% paraformaldehyde in 0.1 M sodium phosphate buffer
(pH 7.4) (18). Organotypic cultures were fixed in the perfusion
solution for 30 min. Abs included rabbit anti-CRF (1:40,000,
W. W. Vale, Salk Institute for Biological Studies, San Diego),
goat anti-CRF1 (1:10,000, Santa Cruz Biotechnology), mouse
anti-vimentin (1:100, Developmental Studies Hybridoma Bank,
Iowa City, IA), mouse anti-SMI32 (1:2,000, Sternberger Mono-
clonals, Baltimore), and rabbit anti-calbindin D-28K (1:8,000,
Chemicon). Immunocytochemistry was performed on free-
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f loating sections (20 m; ref. 18) by using standard avidin–biotin
methods. Double labeling of CRF1 and vimentin (delineates
radial glia; ref. 35) or SMI32 (a marker of subgroup of pyramidal
neurons; ref. 36) were performed as described (18). Visualiza-
tion used Alexa Fluor 488-anti-goat IgG and Alexa Fluor
568-anti-mouse IgG (Molecular Probes). Images were obtained
by using a Zeiss LSM510 Meta confocal microscope.
Golgi Impregnation. P6–P7 CRF1() (n  4) and WT (n  5)
mice were processed for Golgi staining (37), in parallel and
‘‘blindly.’’ After immersion in Golgi–Cox solution (9 d) and 30%
sucrose (2 d), both in the dark, coronal sections (200 m) were
processed in 10% NH4OH (30 min) and then fixed (Kodak
Fix, Kodak). For organotypic cultures, Golgi-gold toning was
used (8).
Quantitative and Statistical Analyses. Individual Golgi-impreg-
nated cells were reconstructed blindly by using camera lucida.
Neurons for analysis were chosen by using unbiased systematic
sampling (8–12 neurons per region per animal; ref. 18). For
cultures, 9–18 neurons per region per group were analyzed. Sholl
analysis (38), a method providing quantitative description of the
dendritic tree by evaluating the number of dendrites that cross
or branch within virtual concentric circles drawn at fixed dis-
tances from the cell body, was used. Numbers of primary
dendrites, total dendritic length, and number of dendritic inter-
sections at each concentric circle (20 m, 40 m, 60 m, etc.)
were measured. An independent analysis of average dendritic
length used the calcium-binding protein calbindin D-28K, which
serves as dendritic marker in developing hippocampal neurons.
Dendritic length (distance from dendritic tip to cell body) was
measured at three points (midpoint of the granule cell layer and
two equidistant points 60 m away) and averaged for compar-
ison among experimental groups. Differences among groups
were compared by using two-way ANOVA (for genotype
treatment and distance from soma), with post hoc analyses
(PRISM, GraphPad, San Diego). Dendritic length and primary
dendrites were compared by using Student’s t test. Data are
expressed as mean  SEM.
Results
CRF and Its Receptor, CRF1, Are Expressed in the Early Postnatal
Hippocampus. During the first postnatal week, a population of
CRF-expressing neurons, many with characteristics of CR
cells, occupied the area abutting the hippocampal fissure (Fig.
1 A and B). These cells comprise the majority of CRF-
expressing cells in hippocampus at this age (18). The actions
of CRF on hippocampal neurons are mediated mainly by the
type 1 receptor, CRF1. Therefore, if CRF contributes to early
postnatal hippocampal development, then CRF1 should be
expressed during these periods, and its distribution and sub-
cellular localization may provide clues for the nature of CRF
Fig. 1. CRF and its receptor, CRF1, are present in early postnatal hippocampus. (A) Diagram illustrates the organization of the developing hippocampus. CR
cells expressing CRF (in blue) are highlighted by arrows. (B) In P5 rat hippocampus, many CRF-immunoreactive neurons resemble CR cells (arrows). (C–H)
Distribution of CRF1 in neonatal hippocampus supports a role for CRF in dendritic development. In P1 (C, G, and H) and P5 (D–F), CRF1 is expressed primarily in
dendrites of pyramidal (arrows) and granule cells. Confocal images indicate that CRF1 (green) is colocalized with neurofilament SMI32 (red, E and F), a pyramidal
cell marker, but not with vimentin (red, G and H), a glia marker. *, hippocampal fissure; SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum; SLM,
stratum lacunosum-moleculare; OML, outer molecular layer; GCL, granule cell layer. (Scale bars: B and C, 75 m; D–F, 25 m; G, 100 m; H, 50 m.)
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inf luence on hippocampal organization. Indeed, CRF1 was
detected in principal hippocampal neurons (Fig. 1 C–F) but
not in radial glia (Fig. 1 G and H). Interestingly, in the P1 rat,
CRF1 was localized primarily to dendrites (Fig. 1C), whereas
at older ages, it was found also perisomatically (Fig. 1 D–F).
This early dendritic localization of CRF1 suggested a role for
its ligand, CRF, in dendritic development.
CRF1 Receptor Deletion Results in Increased Dendritic Length and
Arborization. If CRF is involved in shaping dendritic develop-
ment, then mice lacking CRF or CRF1 should have altered
dendrites. At P6, whereas CRF1() hippocampi exhibited
normal lamination and cell orientation, the size and organization
of dendritic trees were abnormal (Fig. 2 A1–A3 and B1–B3).
Numbers of primary dendrites and total dendritic length of CA1
pyramidal cells in CRF1() mice were higher than in WT
littermates (P  0.01, Fig. 2A3). Using Sholl analysis (38),
two-way ANOVA indicated that the null genotype significantly
affected the number of dendritic intersections. The analysis
further pinpointed this effect to increased proximal dendrites
(Fig. 2A3). Similarly, in CA3 pyramidal cells, numbers of
dendritic intersections at 20–80 m from the soma in
CRF1() mice exceeded those of WT controls (Fig. 2B3).
Granule cells were analyzed at comparable locations within the
granule cell layer, and only in the earlier-maturing suprapyra-
midal blade to avoid maturational differences (Fig. 2 C1–C3).
Lack of CRF1 led to significant increase of secondary dendrites.
Two-way ANOVA of the number of dendritic intersections
showed a strong effect of genotype (F[1, 48] 15.88; P 0.0002).
CRF1 Receptor Blockade Augments the Proximal Dendritic Trees of
Pyramidal Neurons. The enlarged dendritic tree in CRF1()
mice suggested that lack of actions of CRF via CRF1 may
influence dendritic differentiation. However, genetically engi-
neered mice may possess characteristics that are independent of
the function of the deleted gene (39, 40). Therefore, we inves-
tigated the role of CRF1-mediated actions of CRF on dendritic
development by using hippocampal organotypic culture. In
cultures obtained on P1 and grown for 7 d, CRF was expressed
in a pattern recapitulating in vivo hippocampus, including CRF-
expressing CR cells near the hippocampal fissure (Fig. 3).
Exposure of cultures to CRF1 antagonist NBI 30775 (0.1 or 1
M) for 6 d strongly modified the dendritic tree of principal cells,
leading to hyperarborization (Fig. 4) and increased dendritic
length of granule cells (Fig. 5 C1 and C2). CRF1 blockade
increased the number of primary dendrites, total dendritic
length, and number of dendritic intersections at 60 m from the
soma of CA1 pyramidal neurons (Fig. 4A3). The CRF1 antag-
onist also influenced CA3 pyramidal neurons (Fig. 4B3) and
exerted a dose-dependent increase of dendritic length of granule
cells as measured by using the dendritic marker calbindin D-28K
(Fig. 5 C1 and C2).
Altered Dendritic Development of Pyramidal Neurons in the Presence
of CRF. If CRF (via CRF1) contributes to the selective process by
which hippocampal dendrites develop or persist, then the pres-
Fig. 2. Numbers of proximal dendrites and dendritic length in hippocampal pyramidal cells are higher in CRF1() mice. Photographs (light microscopy) show
Golgi-impregnated CA1 (A1 and A2) and CA3 (B1 and B2) pyramidal neurons and dentate gyrus granule cells (C1 and C2) from P6 CRF1() (A1, B1, and C1)
and CRF1() (A2, B2, and C2) mice. Proximal dendrites and dendritic length are higher (*, P  0.05; **, P  0.01) in CA1 and CA3 pyramidal neurons from
CRF1() mice (A3 and B3). CRF1 deletion has a significant effect on numbers of intersections in CA1 (F[1, 56] 61.97; P 0.0001) and CA3 (F[1, 49] 62.71; P
0.0001). These differences stem from increased proximal dendrites (*, P  0.05; **, P  0.01; Bonferroni’s post hoc test). In dentate gyrus (C3), the number of
secondary dendrites is significantly higher in CRF1() mice than in WT controls. Two-way ANOVA demonstrates an overall effect of CRF1 deletion on numbers
of dendritic intersections (F[1, 48]  15.88; P  0.0002). n  8–10 cells per region per animal [n  5 WT and 4 CRF1()]. Arrows, basal dendrites in CRF1()
mice. (Scale bars: A1 and A2, 40 m; B1 and B2, 30 m; C1 and C2, 25 m.)
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ence of supranormal levels of the peptide should reduce the
number and perhaps differentiation of dendrites. Indeed, 6 d in
the presence of CRF (1 M) reduced total dendritic length and
primary branches in pyramidal cells (Fig. 5 A1–A3 and B1–B3),
and using dendritic markers, reduced average dendritic length of
granule cells (Fig. 5 C1 and C2). Again, the principal effect was
on proximal dendrites: fewer intersections at 20, 40, and 60 m
in the CRF group (Bonferroni’s post hoc test).
Discussion
The major findings of this study are as follows. (i) In early postnatal
hippocampus, CRF is expressed by CR cells, and its principal
receptor, CRF1, is found in neurons but not in radial glia. (ii)
Absence (in vivo) or pharmacological blockade (in vitro) of CRF1
leads to exuberant dendritic arborization. (iii) High levels of CRF
have the opposite effect, reducing dendritic differentiation. (iv)
These effects are primarily on proximal dendritic segments and do
not influence hippocampal lamination. Taken together, these find-
ings suggest that endogenous CRF, which may be released exces-
sively in developing hippocampus by stress, may influence hip-
pocampal dendritic differentiation.
The distribution and function of CRF in mature hippocampus
are being progressively elucidated. In juvenile and adult hip-
pocampus, CRF is primarily expressed in GABAergic interneu-
rons (18, 25, 26). When released from GABAergic terminals
(41), CRF acts as an excitatory neuromodulator: Although not
provoking action potentials, CRF amplifies excitatory signals
that may then reach firing threshold (1, 24). These actions of
CRF enhance normal synaptic function, promoting learning and
memory processes (e.g., refs. 28 and 29). Under pathological
conditions, these actions may also underlie the proconvulsant
effects of the peptide (27). In general, the effects of CRF are
mediated via binding to G-protein-coupled CRF receptors,
CRF1 and CRF2 (42). CRF1 is predominant in rodent hippocam-
pus (43–45), where it is selectively responsible for mediating the
actions of the peptide (46–48). Recent studies show that CRF1
is preferentially located on dendritic spines, in close to excitatory
synapses (41). These data indicate that on release from periso-
matic GABAergic terminals, CRF needs to traverse a substantial
distance to reach its receptor, assuring that only under condi-
tions of extensive release, e.g., during stress, will sufficient
peptide amounts reach CRF1 to enhance synaptic efficacy. Thus,
in mature hippocampus, CRF and CRF1 may constitute an
important element of the molecular machinery that mediates
stress-related synaptic plasticity (29, 41).
Early in postnatal life, CRF expression differs from the mature
pattern (18): During the first postnatal week, most CRF-
expressing hippocampal neurons are CR cells, whose numbers
decline drastically thereafter. This unique expression pattern of
CRF raised the possibility of development-specific functions,
and a dendritic-modulating role has been proposed in cerebel-
lum (49–51). The exclusive location of CRF1 on neuronal
dendrites excluded the possibility that CRF might act in concert
on radial glia differentiation, suggesting instead that early post-
natal CRF may influence the maturation of hippocampal neu-
rons, specifically dendrites, directly.
The current studies provide evidence for a role of CRF in
dendritic growth and pruning. In the absence of CRF-evoked
CRF1-mediated neuromodulation, i.e., in CRF1() mice or
when hippocampi are grown in vitro in the presence of CRF1
antagonists, dendritic branching and total dendritic length were
increased. In contrast, increasing CRF levels artificially during
the first postnatal week blunted dendritic growth. How do these
findings, together with the known functions of CRF on synaptic
Fig. 3. The in vivo expression pattern of CRF is recapitulated in organotypic
cultures. The hippocampal slice was harvested at P1, cultured for 7 d, and then
subjected to CRF immunocytochemistry (with methyl green counterstain).
CRF-expressing neurons (arrow) with characteristics of CR cells are found close
to the hippocampal fissure (broken line). SLM, stratum lacunosum-moleculare;
OML, outer molecular layer; GCL, granule cell layer. (Scale bar: 60 m.)
Fig. 4. CRF1 blockade increases the number of proximal dendrites (arrows) of CA1 and CA3 pyramidal cells. Slice cultures from P1 hippocampi were grown in
the presence of 0.1 or 1 M CRF1 antagonist NBI 30775 (A2 and B2) and controls (A1 and B1). Because of their indistinguishable effects, the two doses were
combined for analysis. NBI 30775 treatment increased total dendritic length (*, P 0.05) and proximal dendritic intersections (F[1, 192] 24.77; P 0.0001) in CA1
pyramidal cells (A3). Similarly increased were the number of dendritic intersections in CA3 (B3) (F[1, 275]  45.81; P  0.0001). n  9–18 neurons per treatment
per region. SP, stratum pyramidale. (Scale bars: A1 and A2, 45 m; B1 and B2, 55 m.)
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efficacy, inform us about the role of the peptide in dendritic
differentiation?
The developing dendritic arbor is a dynamic structure (52),
governed by both intrinsic genetic programs and extrinsic signals
(53, 54). Dendrites actively contribute to initial synaptogenic
intercellular contacts via immature dendritic protrusions. Be-
cause the majority of contacts do not survive, selective stabili-
zation of these immature synapses may be a key element in the
generation of mature dendritic structures (55). The molecules
and mechanisms for this selective stabilization are not fully
understood and include neuronal activity (8, 56). Thus, genetic
programs and guidance cues influence early phase of dendritic
growth whereas activity-mediated increase of strength of select
synapse may govern final neuronal connectivity (53).
The current studies suggest a role for CRF in this later phase
of dendritic differentiation: The ‘‘hyperarborization’’ when
CRF1 is absent or blocked suggests a lack of selective stabiliza-
tion of synaptic contacts. This possibility is attractive because it
is consonant with the established roles of the peptide in mature
hippocampus, i.e., increasing synaptic efficacy (24, 28, 29). Thus,
immature dendritic contacts expressing CRF1 are preferentially
strengthened and stabilized by ambient CRF, compared to those
lacking the receptor. Alternatively, the peptide might function to
inhibit nonstabilized connections: In the absence of CRF or
CRF1, excessive numbers of dendritic elements would persist as
found here. In contrast, under conditions of pathological release
of CRF, as occurs in immature hippocampus during stress (20, 41),
excessive strengthening of few synapses andor excessive pruning
might contribute to stress-associated dendritic atrophy (57).
The downstream effects of CRF1 activation on developing
dendrites are unknown. Increased cellular cAMP levels (58, 59),
promoting phosphorylation of cAMP-response element-binding
protein transcription factor (41, 60, 61) is an attractive possibil-
ity, because cAMP-response element-binding protein is selec-
tively activated in developing hippocampal neurons (62) and is
involved in dendritic differentiation (63). The selective effects of
CRF on proximal dendrites may be dictated by the selective
distribution of CRF1 at this age (Fig. 1). This intriguing laminar
selectivity also suggests that CRF and CRF1 may influence the
selective termination of associationalcommissural connections
on proximal dendrites (6, 17).
In summary, the hippocampal neuromodulator CRF acts via
the CRF1 receptor to influence the structure of dendritic trees
in developing hippocampal neurons. Because this peptide’s
release is regulated by environmental signals, it might contribute
to neuroplasticity of hippocampal synaptic connectivity. In ad-
dition, under pathological conditions, excessive CRF release may
contribute to abnormal dendritic patterns in certain human
neurological disorders (64, 65).
We thank R. Gonzalez-Vega for excellent technical assistance. This work
was supported by National Institutes of Health Grants NS28912 and
NS39307 (to T.Z.B.).
Fig. 5. Addition of synthetic CRF (A2 and B2) to hippocampal slice cultures reduces dendritic branching and length, evident from both Golgi impregnation and
quantification of a dendritic marker. CRF exposure reduces number of primary dendrites (, P 0.056), total dendritic length (*, P 0.05), and overall number
of intersections (F[1, 360]  13.50; P  0.0003) (A3) in CA1. In CA3, number of primary dendrites (*,P  0.05), dendritic length (**, P  0.01), and number of
intersections (F[1, 330] 21.52; P 0.0001) (B3) are reduced. Cultures were grown with CRF (1 M, added on day 2) or CRF1 antagonist (0.01, 0.1, or 10 M). n
16 neurons per treatment per region. (C) Differential and opposing effects of CRF and CRF1 antagonist on dendritic growth also are evident when the dendritic
marker calbindin D-28K is used (shown here for the granule cell dendrites in suprapyramidal blade of dentate gyrus). C1 illustrates calbindin-immunoreactive
granule cells dendrites in a control culture. Lines from cell body to the tip of the dendrites were used to assess dendritic length. (C2) Exposure to CRF1 antagonist
increases average dendritic length in a dose-dependent manner, whereas growing cultures in the presence of CRF reduces dendritic length (*, P  0.05). SP,
stratum pyramidale; GCL, granule cell layer. (Scale bars: A1 and A2, 45 m; B1 and B2, 55 m; C1, 25 m.)
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